MoFo Life Sciences

November 03, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations
By: Otis Littlefield Ph.D. and Michael Ward Ph.D.
In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and Patent Group, discusses these issues among others with:
... ›
October 22, 2020 - AI + Robotics, Licensing + Commercial, FDA, COVID-19, Intellectual Property, Privacy + Data Security
Podcast: Applying AI and Data Science to the Fight Against COVID-19: The Science and Legal Considerations
By: Jean Nguyen Ph.D., Matt Karlyn and Michael Ward Ph.D.
In this second of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each unique aspect of the current health crisis, Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and
... ›
October 17, 2020 - Licensing + Commercial, United States, Corporate + Venture Capital
Life Sciences Startup: Top Things to Keep in Mind About Formation and License Agreements
By: Steve Rowles, Matt Karlyn and Michael Ward Ph.D.
During our fifth Patent Law Course session offered by Morrison & Foerster and GSAS Harvard Biotech Club , Steve Rowles, firmwide co-chair of the Emerging Companies & Venture Capital Group , chair of MoFo’s San Diego Corporate Group, and managing partner of the San
... ›
October 13, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property, Privacy + Data Security
Podcast: Unpacking the Science and Legal Considerations of COVID-19 Testing
By: Matt Karlyn and Michael Ward Ph.D.
In this first of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each unique aspect of the current health crisis, Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and
... ›
September 22, 2020 - Licensing + Commercial, United States, FDA, Startup, Data Analytics, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!
By: Michael Ward Ph.D., Matt Karlyn, Janet Xiao Ph.D., Matthew A. Chivvis, Jie Zhou Ph.D., Anna Yuan and Jillian A. Pesin-Fulop Ph.D.
More than 120 life sciences graduate students, post-docs and industry professionals attended the first class of a six part Patent Law Course offered by Morrison & Foerster and the GSAS Harvard Biotech Club on September 16, 2020. The Harvard Biotech Club is a student
... ›
August 07, 2020 - Licensing + Commercial, United States, Litigation
California Supreme Court Clarifies Standards for B2B Non-Competition Agreements and Disputes in California
By: Eric Akira Tate
This week, on August 3, 2020, the California Supreme Court issued its opinion in Ixchel Pharma, LLC v. Biogen, Inc. , which resolved two questions regarding the standards to be applied for non-competition agreements and disputes between businesses in California. The first was whether
... ›
December 12, 2019 - Licensing + Commercial, Intellectual Property, Asia
Crossing Borders
By: Janet Xiao Ph.D.
Partner Janet Xiao, who leads the firm’s China Life Sciences Group, co-authored an article with associate Can Cui for Intellectual Property Magazine , titled “Crossing Borders,” which explores technology transfer opportunities emerging from import rules in China. The authors note that Chinese companies are
... ›
October 01, 2019 - Licensing + Commercial, Biotech, Regulatory, Intellectual Property, Asia
China Patent Eligibility Update: Human Embryonic Stem Cells
On September 23, 2019, China National Intellectual Property Administration (“CNIPA”) announced its proposed amendments to China’s Guideline on Patent Examination (the “Guideline”), which is the counterpart of the Manual of Patent Examining Procedure in the U.S. The proposed amendments will become effective November 1,
... ›
August 02, 2017 - Licensing + Commercial, European Union, Regulatory
IP Licensing and Antitrust Law – What Companies Have to Consider When Doing Business in the U.S. and the EU
By: Jens Hackl, Wolfgang Schönig and Jeff Jaeckel
In both the U.S. and the EU, it is generally acknowledged that the enforcement and commercialization of IP rights must comply with the applicable antitrust laws. This is particularly true for IP licensing. While the majority of provisions in license arrangements will not be
... ›

Topic Archives: Licensing + Commercial

Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations

By: Otis Littlefield Ph.D. and Michael Ward Ph.D.

Podcast: Applying AI and Data Science to the Fight Against COVID-19: The Science and Legal Considerations

By: Jean Nguyen Ph.D., Matt Karlyn and Michael Ward Ph.D.

Life Sciences Startup: Top Things to Keep in Mind About Formation and License Agreements

By: Steve Rowles, Matt Karlyn and Michael Ward Ph.D.

Podcast: Unpacking the Science and Legal Considerations of COVID-19 Testing

By: Matt Karlyn and Michael Ward Ph.D.

GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!

By: Michael Ward Ph.D., Matt Karlyn, Janet Xiao Ph.D., Matthew A. Chivvis, Jie Zhou Ph.D., Anna Yuan and Jillian A. Pesin-Fulop Ph.D.

California Supreme Court Clarifies Standards for B2B Non-Competition Agreements and Disputes in California

By: Eric Akira Tate

Crossing Borders

By: Janet Xiao Ph.D.

China Patent Eligibility Update: Human Embryonic Stem Cells

IP Licensing and Antitrust Law – What Companies Have to Consider When Doing Business in the U.S. and the EU

By: Jens Hackl, Wolfgang Schönig and Jeff Jaeckel